Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma

URSULA PLUSCHNIG, SEBASTIAN F. SCHOPPMANN, MATTHIAS PREUSSER, PHILIP DATLER, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, PETER BIRNER, JOHANNES ZACHERL and MICHAEL HEJNA
Anticancer Research March 2013, 33 (3) 1035-1039;
URSULA PLUSCHNIG
1Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEBASTIAN F. SCHOPPMANN
2Department of General Surgery, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MATTHIAS PREUSSER
1Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PHILIP DATLER
1Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
REZA ASARI
2Department of General Surgery, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AHMED BA-SSALAMAH
3Department of Radiology, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATRIN SCHWAMEIS
2Department of General Surgery, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PETER BIRNER
4Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHANNES ZACHERL
2Department of General Surgery, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL HEJNA
1Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria
5Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.hejna@meduniwien.ac.at
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Progression-free survival (months).

Tables

  • Figures
  • Table I.
  • Table II.
PreviousNext
Back to top

In this issue

Anticancer Research: 33 (3)
Anticancer Research
Vol. 33, Issue 3
March 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma
URSULA PLUSCHNIG, SEBASTIAN F. SCHOPPMANN, MATTHIAS PREUSSER, PHILIP DATLER, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, PETER BIRNER, JOHANNES ZACHERL, MICHAEL HEJNA
Anticancer Research Mar 2013, 33 (3) 1035-1039;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma
URSULA PLUSCHNIG, SEBASTIAN F. SCHOPPMANN, MATTHIAS PREUSSER, PHILIP DATLER, REZA ASARI, AHMED BA-SSALAMAH, KATRIN SCHWAMEIS, PETER BIRNER, JOHANNES ZACHERL, MICHAEL HEJNA
Anticancer Research Mar 2013, 33 (3) 1035-1039;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract
  • Google Scholar

More in this TOC Section

  • Predictive and Prognostic Value of SUOX Expression in Pancreatic Ductal Adenocarcinoma
  • Liberal Application of Portal Vein Embolization for Right Hepatectomy Against Hepatocellular Carcinoma: Strategy to Achieve Zero Mortality for a Damaged Liver
  • Pancreaticoenterostomy With Seromuscular-parenchymal Anastomosis for Prevention of Postoperative Pancreatic Fistula in Distal Pancreatectomy
Show more Clinical Studies

Similar Articles

Keywords

  • Epirubicin
  • oxaliplatin
  • capecitabine
  • Gastroesophageal cancer
  • adenocarcinoma
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire